MPLTMapLight Therapeutics, Inc.
Earnings
When MapLight Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.
11 quarters. Mar 31, 2024 to Sep 30, 2026. mixed units.
Latest results
- Revenue
- —
- —
- Net income
- -$51.62M
- N/M
- EPS
- -$0.97
- N/M
- Revenue
- —
- —
- Net income
- -$60.19M
- N/M
- EPS
- -$1.32
- N/M
- Revenue
- —
- —
- Net income
- -$60.67M
- N/M
- EPS
- -$1.34
- N/M
- Revenue
- —
- —
- Net income
- -$79.55M
- N/M
- EPS
- —
- —
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | Sep 30, 2026 | Nov 16, 2026 · pre-market | Nov 16, 2026 | 47 d | 10-Q | — | — | -$0.97 | — | |
| Q2 2026 | Jun 30, 2026 | Aug 13, 2026 · after-hours | Aug 13, 2026 | 44 d | 10-Q | — | — | -$1.32 | +1.3% | |
| Q1 2026 | Mar 31, 2026 | May 14, 2026 · after-hours | May 14, 2026 | 44 d | 10-Q | — | — | -$1.34 | 1.9% | |
| FY 2025 | ||||||||||
| Q4 2025derived | Dec 31, 2025 | Mar 26, 2026 · pre-market | Mar 26, 2026 | 85 d | 10-K | — | — | — | +6.0% | |
| Q3 2025 | Sep 30, 2025 | Dec 4, 2025 · pre-market | Dec 4, 2025 | 65 d | 10-Q | — | — | -$37.18 | +8.2% | |
| Q2 2025 | Jun 30, 2025 | — | — | — | — | — | — | -$39.11 | — | |
| Q1 2025 | Mar 31, 2025 | — | — | — | — | — | — | -$29.33 | — | |
| FY 2024 | ||||||||||
| Q4 2024derived | Dec 31, 2024 | — | — | — | — | — | — | — | — | |
| Q3 2024 | Sep 30, 2024 | — | — | — | — | — | — | -$25.08 | — | |
| Q2 2024 | Jun 30, 2024 | — | — | — | — | — | — | — | — | |
| Q1 2024 | Mar 31, 2024 | — | — | — | — | — | — | — | — | |
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
MapLight Therapeutics, Inc. · CIK 1770069 · Engraved from SEC EDGAR